Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant
← catalyst calendarNCT07430059 · readout ≤ 134 d
Sponsored by Vivani Medical, Inc (industry) · VANI — their whole pipeline →. With Avance Clinical Pty Ltd..
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
20estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jul 2026 | estimated | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity & Overweight
Interventions
- Combination product: Semaglutide Implant (NPM-139)
- Drug: Semaglutide (Wegovy) weekly injection
Primary outcomes
what the primary-completion date above is the date OFArea under the plasma concentration-time curve (AUC)
measured 4 weeks
Maximum plasma concentration (Cmax)
measured 4 weeks
Time to maximum semaglutide concentration (Tmax)
measured 4 weeks
Adverse Events
measured 4 weeks
Permalink · VANI's whole pipeline · Catalyst calendar · Every registered study · What changed